EUCTR2015-004553-41-BG进行中（未招募）1 期
A Phase 2 Open-label study to Evaluate the Safety of Aceneuramic Acid ExtendedRelease (Ace-ER) Tablets in GNE Myopathy (GNEM) (also known as HereditaryInclusion Body Myopathy (HIBM)) patients with Severe Ambulatory Impairment
ltragenyx Pharmaceutical Inc.0 个研究点目标入组 45 人开始时间: 2016年9月14日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female, aged = 18 years old
- •2. Willing and able to provide written, signed informed consent after the nature of the study has been explained, and before any research-related procedures are conducted
- •3. Have a documented diagnosis of GNEM, HIBM, distal myopathy with rimmed vacuoles (DMRV), or Nonaka disease due to previously demonstrated mutations in the gene encoding the GNE/MNK enzyme (genotyping will not be conducted in this study).
- •4. Should meet the criteria for severe ambulatory impairment defined below:
- •Unable to rise from a seated position to standing without help from another person, assistive device(s), stationary object, or other support
- •Unable to walk without the assistance of another person OR if able to walk (use of assistive device(s) permitted), requires at least 2 minutes to walk 40 meters (one full lap of the 6MWT course)
- •Use of wheelchair or scooter for activities outside of the home or unable to leave the home independently
- •5. Willing and able to comply with all study procedures
- •6. Participants of childbearing potential or with partners of childbearing potential who have not undergone a bilateral salpingooophorectomy and are sexually active must consent to use highly effective method of contraception as determined by the site investigator (i.e. oral hormonal contraceptives, patch hormonal contraceptives, vaginal ring, intrauterine device, physical doublebarrier methods, surgical hysterectomy, vasectomy, tubal ligation or true abstinence (when this is in line with the preferred and usual lifestyle of the subject) which means not having sex because the subject chooses not to), from the period following the signing of the informed consent through 30 days after last dose of study drug
- •7. Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause for at least two years, have had tubal ligation at least one year prior to Screening, or who have had a total hysterectomy or bilateral salpingooophorectomy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 43
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •1. Ingestion of N-acetyl-D-mannosamine (ManNAc), SA, or related metabolites; intravenous immunoglobulin (IVIG); or anything that can be metabolized to produce SA in the body within 60 days prior to the Screening Visit
- •2. Prior participation in a clinical trial involving treatment with Ace-ER/placebo and/or Sialic Acidimmediate release (SA-IR) in the past year
- •3. Has had any hypersensitivity to SA or its excipients that, in the judgment of the investigator, places the subject at increased risk for adverse effects
- •4. Has serum transaminase (i.e. aspartate aminotransferase [AST] or gamma-glutamyl transpeptidase [GGT]) levels greater than 3X the upper limit of normal (ULN) for age/gender, or serum creatinine of greater than 2X ULN at Screening
- •5. Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study
- •6. Use of any investigational product or investigational medical device within 30 days prior to Screening, or anticipated requirement for any investigational agent prior to completion of all scheduled study assessments
- •7. Has a condition of such severity and acuity, in the opinion of the investigator, that it warrants immediate surgical intervention or other treatment or may not allow safe participation in the study
- •8. Has a concurrent disease, active suicidal ideation, or other condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or would affect safety
研究者
相似试验
未知
2 期
A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult SubjectsPrevention of Influenza infectionJPRN-jRCT2080223134TAKEDA PHARMACEUTICAL COMPANY LTD.55
进行中（未招募）
1 期
A study to understand the safety and effectiveness of switching to a new drug called Vemlidy from an existing drug called Viread or other oral antiviral treatments drugs for the treatment of long term hepatitis B infection in subjects with renal and/or hepatic impairmentChronic Hepatitis BMedDRA version: 20.0Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-004625-16-GBGilead Sciences, Inc.120
进行中（未招募）
1 期
A study to understand the safety and effectiveness of switching to a new drug called Vemlidy from an existing drug called Viread or other oral antiviral treatments drugs for the treatment of long term hepatitis B infection in subjects with renal and/or hepatic impairmentChronic Hepatitis BMedDRA version: 20.1Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-004625-16-ITGILEAD SCIENCES INCORPORATED120
进行中（未招募）
1 期
Pembrolizumab in combination with vibostolimab in relapsed or refractory hematologic malignanciesEUCTR2021-001700-15-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.180
进行中（未招募）
1 期
Pembrolizumab in combination with vibostolimab in relapsed or refractory hematologic malignanciesRelapsed/refractory hematological malignanciesMedDRA version: 21.1Level: LLTClassification code 10066481Term: Hematological malignancySystem Organ Class: 100000004864EUCTR2021-001700-15-DEMerck Sharp & Dohme LLC180